Altered Neuropsychological Performance and Reduced Brain Volumetrics in People Living with HIV on Integrase Strand Transfer Inhibitors

Overview

Journal AIDS

Specialty Infectious Diseases

Date 2019 Apr 23

PMID 31008801

Citations 23

Authors

Jane A OHalloran

Sarah A Cooley

Jeremy F Strain

Anna Boerwinkle

Robert Paul

Rachel M Presti

Beau M Ances

Affiliations

Soon will be listed here.

Abstract

Objectives: Neuropsychiatric symptoms have been reported in people living with HIV (PLWH) on integrase strand transfer inhibitors (INSTIs) in postmarketing analysis. Limited data exist regarding brain integrity (function and structure) in PLWH prescribed INSTIs compared with other HIV treatment regimens.

Design: A cross-sectional analysis of PLWH on combined antiretroviral therapy aged more than 18 years at a single institution.

Methods: Neuropsychological tests were administered to calculate domain deficit scores in learning/memory, executive function and motor/psychomotor domains. Cortical and subcortical volumes from MRI were obtained using the FreeSurfer software suite (v5.3).

Results: Of 202 participants, median age 55 (48, 60) years old, 49% were on INSTI-based combined antiretroviral therapy. PLWH on INSTIs were similar to individuals on non-INSTIs in terms of age, sex, race, education years, smoking history, depression scores, psychiatric medication use, presence of hepatitis C infection, history of substance use, HIV infection duration and recent or nadir CD4 T-cell count. Participants in the INSTI group performed worse than non-INSTI users in the verbal learning and memory domain [1.5 (interquartile range 0, 2.5) versus 1 (0, 2); P = 0.016]. The INSTI and non-INSTI groups were similar for other cognitive domains. Frontal, brain stem and cerebellar volumes were reduced in INSTI compared with non-INSTI users (all P = <0.05).

Conclusion: We demonstrated modest differences in learning/memory performance and smaller brain volumes in PLWH on INSTI-based regimens compared with non-INSTI users. Prospective studies are needed to define mechanisms and the clinical significance of reduced brain integrity in PLWH on INSTIs.

Citing Articles

The differential effects of integrase strand transfer inhibitors and efavirenz on neuropsychiatric conditions and brain imaging in HIV-positive men who have sex with men.

He Y, Zhang Y, Zhen J, Sun G, Li Z, Yang B Biosaf Health. 2025; 6(4):216-224.

PMID: 40078667 PMC: 11894960. DOI: 10.1016/j.bsheal.2024.07.001.

Factors Associated with Time to Initial Antiretroviral Therapy Discontinuation in the DC Cohort.

Byrne M, Resnik J, Horberg M, Greenberg A, Castel A, Monroe A AIDS Res Hum Retroviruses. 2024; 40(12):671-679.

PMID: 38959120 PMC: 11693942. DOI: 10.1089/AID.2024.0002.

Inhibition of lipid synthesis by the HIV integrase strand transfer inhibitor elvitegravir in primary rat oligodendrocyte cultures.

Monnerie H, Romer M, Roth L, Long C, Millar J, Jordan-Sciutto K Front Mol Neurosci. 2023; 16:1323431.

PMID: 38146334 PMC: 10749327. DOI: 10.3389/fnmol.2023.1323431.

An Integrative Approach to the Current Treatment of HIV-Associated Neurocognitive Disorders and the Implementation of Leukemia Inhibitor Factor as a Mediator of Neurocognitive Preservation.

De Freitas-Suarez A, Espinosa-Ponce N, Alvarez-Roger N, Cabrera-Suarez A, Jimenez-Jordan G, Vega-Roman R Life (Basel). 2023; 13(11).

PMID: 38004334 PMC: 10672511. DOI: 10.3390/life13112194.

Impact of Integrase Strand Transfer Inhibitors on Cognition in the HAILO Cohort.

OHalloran J, Parra-Rodriguez L, Goss C, Agarwal M, Cooley S, Wu K J Acquir Immune Defic Syndr. 2023; 94(5):437-444.

PMID: 37949447 PMC: 11303936. DOI: 10.1097/QAI.0000000000003297.

References

Calcagno A, Cusato J, Simiele M, Motta I, Audagnotto S, Bracchi M . High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. J Antimicrob Chemother. 2013; 69(1):241-5. DOI: 10.1093/jac/dkt339. View

Gray J, Young B . Acute onset insomnia associated with the initiation of raltegravir: a report of two cases and literature review. AIDS Patient Care STDS. 2009; 23(9):689-90. DOI: 10.1089/apc.2009.0012. View

Gladsjo J, Schuman C, Evans J, Peavy G, Miller S, Heaton R . Norms for letter and category fluency: demographic corrections for age, education, and ethnicity. Assessment. 1999; 6(2):147-78. DOI: 10.1177/107319119900600204. View

Beck A, Steer R, Ball R, Ranieri W . Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996; 67(3):588-97. DOI: 10.1207/s15327752jpa6703_13. View

Piatt A, Fields J, Paolo A, Troster A . Action (verb naming) fluency as an executive function measure: convergent and divergent evidence of validity. Neuropsychologia. 2000; 37(13):1499-503. DOI: 10.1016/s0028-3932(99)00066-4. View

Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, Bracciale L . Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology. 2011; 76(16):1403-9. DOI: 10.1212/WNL.0b013e31821670fb. View

Walmsley S, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F . Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013; 369(19):1807-18. DOI: 10.1056/NEJMoa1215541. View

Sanford R, Fellows L, Ances B, Collins D . Association of Brain Structure Changes and Cognitive Function With Combination Antiretroviral Therapy in HIV-Positive Individuals. JAMA Neurol. 2017; 75(1):72-79. PMC: 5833491. DOI: 10.1001/jamaneurol.2017.3036. View

Vera J, Jackson A, Dickinson L, Else L, Barber T, Mora-Peris B . The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. HIV Clin Trials. 2015; 16(1):39-42. DOI: 10.1179/1528433614Z.0000000006. View

10.

Ma Q, Vaida F, Wong J, Sanders C, Kao Y, Croteau D . Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol. 2015; 22(2):170-8. PMC: 4783211. DOI: 10.1007/s13365-015-0382-7. View

11.

Raffi F, Rachlis A, Stellbrink H, Hardy W, Torti C, Orkin C . Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013; 381(9868):735-43. DOI: 10.1016/S0140-6736(12)61853-4. View

12.

Carey C, Woods S, Gonzalez R, Conover E, Marcotte T, Grant I . Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004; 26(3):307-19. DOI: 10.1080/13803390490510031. View

13.

Levine A, Hinkin C, Castellon S, Mason K, Lam M, Perkins A . Variations in patterns of highly active antiretroviral therapy (HAART) adherence. AIDS Behav. 2005; 9(3):355-62. DOI: 10.1007/s10461-005-9009-y. View

14.

Hoddes E, Zarcone V, Smythe H, Phillips R, Dement W . Quantification of sleepiness: a new approach. Psychophysiology. 1973; 10(4):431-6. DOI: 10.1111/j.1469-8986.1973.tb00801.x. View

15.

Clifford D, Evans S, Yang Y, Acosta E, Ribaudo H, Gulick R . Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials. 2010; 10(6):343-55. PMC: 2958039. DOI: 10.1310/hct1006-343. View

16.

Norman M, Moore D, Taylor M, Franklin Jr D, Cysique L, Ake C . Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. J Clin Exp Neuropsychol. 2011; 33(7):793-804. PMC: 3154384. DOI: 10.1080/13803395.2011.559157. View

17.

Anderson A, Munoz-Moreno J, McClernon D, Ellis R, Cookson D, Clifford D . Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy. J Infect Dis. 2016; 215(1):105-113. PMC: 5225254. DOI: 10.1093/infdis/jiw505. View

18.

Heaton R, Franklin D, Ellis R, McCutchan J, Letendre S, LeBlanc S . HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2010; 17(1):3-16. PMC: 3032197. DOI: 10.1007/s13365-010-0006-1. View

19.

Sacktor N, Skolasky R, Seaberg E, Munro C, Becker J, Martin E . Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology. 2016; 86(4):334-40. PMC: 4776086. DOI: 10.1212/WNL.0000000000002277. View

20.

Buysse D, Reynolds 3rd C, Monk T, BERMAN S, Kupfer D . The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989; 28(2):193-213. DOI: 10.1016/0165-1781(89)90047-4. View